Next-Generation Regenerative Therapies for Alpha-1 Antitrypsin Deficiency: Molecular Pathogenesis to Clinical...

Area of Science:

• Genetics and Immunology
• Pulmonary Medicine

Background:

• Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder with known liver issues but poorly understood lung effects.
• Neutrophil dysregulation and sustained inflammation in AATD contribute to alveolar destruction and emphysema, a key feature of COPD.
• Defective alpha-1 antitrypsin (AAT) production and Z-AAT polymer accumulation drive pathological cycles, exacerbating inflammation and lung damage.

Purpose of the Study:

• To explore the immunological pathways and inflammatory processes underlying lung disease progression in AATD.
• To investigate the role of neutrophil and monocyte/macrophage dysregulation in AATD-related pulmonary pathology.
• To review recent advances in iPSC technology and gene editing for studying AATD pathogenesis and developing therapeutic strategies.

Main Methods:

• Review of current literature on AATD pathophysiology, focusing on immunological and inflammatory mechanisms.
• Analysis of the role of neutrophils, monocytes, and macrophages in the context of AATD.
• Exploration of induced pluripotent stem cell (iPSC)-derived models and gene editing technologies for AATD research.

Main Results:

• AATD involves neutrophil accumulation and impaired extracellular trap formation (NETosis) due to elastase dysregulation.
• Intracellular Z-AAT polymer accumulation impairs monocyte-derived macrophage function and promotes a pro-inflammatory environment.
• iPSC technology enables generation of alveolar epithelial cells and disease modeling, while gene editing confirms mutation-phenotype causality.

Conclusions:

• Understanding the immunological basis of AATD lung disease is crucial for effective treatment development.
• iPSC-derived models and gene editing are powerful tools for elucidating AATD pathogenesis and testing novel therapies.
• Targeting inflammatory pathways and restoring AAT function hold promise for managing AATD-related pulmonary complications.